007  The MS-STAT2 trial in secondary progressive MS – study design and update. Issue 6 (27th May 2022)

• Record Type: Journal Article
• Authors: Williams, Thomas; John, Nevin; Calvi, Alberto; Doshi, Anisha; Bianchi, Alessia; Brownlee, Wallace; Blackstone, James; Braisher, Marie; Anglias, Floriana De; Chataway, Jeremy
• Is Part Of: Journal of neurology, neurosurgery and psychiatry. Volume 93:Issue 6(2022)
• Page Start: A16
• Page End: A16
• Publication Date: 2022-05-27
• Subjects: Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Psychiatry -- Periodicals; 616.8
• DOI: 10.1136/jnnp-2022-ABN.46
• Languages: English
• ISSNs: 0022-3050

Abstract

Abstract : The MS-STAT2 study is a Phase III, 3 year multi-centre, randomised, placebo-controlled trial assessing the efficacy of 80mg simvastatin vs. placebo in secondary progressive multiple sclerosis (SPMS). Building upon the promising results of the MS-STAT1 study, it is an academically led study funded through a collaboration of the NIHR HTA, MS Society (UK), National MS Society (US), and the Rosetrees Trust. Here we will provide an update on the trial design and progress, including: The agreed trial extension period Adaptations to recruitment targets and trial design An update on trial sites where patients can be referred An update on current trial progress [e-mail]